Decision Benefits Medicaid Patients with Chronic Wounds
NEWPORT NEWS, Virginia (January 1, 2017) – The Florida Agency for Health Care Administration (Florida Medicaid) now provides coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds. This compliments a decision previously taken by Medicare to cover TheraSkin in Minnesota.
The decision by the Florida Medicaid Program will now cover this limb and life-saving product for their more than 3,300,000 Medicaid recipients. Florida residents with diabetic and venous leg ulcers will now have access to clinically and cost-effective living cell therapy. Living cell therapy has been cited as the new standard of care for these types of ulcers.
Patients who will particularly benefit from the wound healing capabilities of TheraSkin are those with diabetes. When conventional therapy fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year. TheraSkin clinical results demonstrate the potential to heal wounds and save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.
TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.